Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart-Lung machine showdown: which oxygenator spares your platelets?

NCT ID NCT05588011

Knowledge-focused Sponsor: BRADEN DULONG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 68 adults having planned heart surgery that required a heart-lung machine. Researchers compared two different oxygenators (artificial lungs) to see if one caused more damage to platelets, the blood cells that help stop bleeding. They used a special test called Plateletworks to measure platelet function during surgery. The goal was to learn which oxygenator is safer and improve how doctors monitor bleeding risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

68 people

The number who actually took part.

Started

Oct 2022

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Scheduled for non emergent cardiac surgery * Anticipated long CPB time (Multi-vessel CABG, multi-valve surgeries, or combined CABG and valve procedures) Exclusion Criteria: * Pregnancy * Age under 18 years on the surgery date * Weight less than 60kg * Any known pre-existing bleeding disorder * Inability to provide informed consent * Pre-existing abnormal fibrinogen level (normal: 1.8-4.7g/l) * Significant liver disease (alanine aminotransferase or aspartate aminotransferase \> 150 U/l) * INR \> 1.4 * PTT greater than 38 (off IV heparin for 12h prior to testing) * Direct oral anticoagulant (DOAC) use within 72h preoperatively * Significant renal disease (eGFR \< 50) * Emergency surgery * Intake of anti-platelet drugs (including ticagrelor and Plavix but excluding ASA) within three days (72h) preoperatively * Anemia (Hb \< 110) * Deep vein thrombosis (DVT) (within 3 months prior to OR) * Pulmonary embolism (within 3 months prior to OR) * Stroke (within 3 months prior to OR) * Planned hypothermia below 28 degrees Celsius.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiopulmonary bypass are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

blood platelet disease qualitative platelet defect

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiopulmonary bypass Platelet dysfunction

Contacts and locations

Locations

  • Halifax Infirmary site, Queen Elizabeth II Health Sciences Centre

    Halifax, Nova Scotia, B3H3A7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.